|
Match
|
Document |
Document Title |
|
|
7642289 |
Drugs for chronic pain
The present invention relates to nitrooxyderivatives or salts thereof having the following general formula (I):
R—NR 1c —(K) k0...
|
|
|
7619007 |
Method and composition for administering an NMDA receptor antagonist to a subject
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
|
|
|
7456223 |
Treatment of bruxism
A composition and its use for local percutaneous delivery of a drug, in particular a muscle relaxant, more particularly cyclobenzaprine present in an amount of about 1 to about 10% by weight of the...
|
|
|
7456224 |
Method for treating autism
A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.
|
|
|
7422110 |
Titration/compliance pack with increasing doses
A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including...
|
|
|
7086532 |
Titration/compliance pack with increasing doses
A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including...
|
|
|
6974814 |
Neuropharmacological treatment of sleep-related breathing disorders
The present invention relates to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess...
|
|
|
6576636 |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.
|
|
|
6531511 |
2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
The use of a compound of formula (1), as disclosed in the specification, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically...
|
|
|
6384083 |
USE OF ADAMANTANE AMINES OR STRUCTURALLY SIMILAR COMPOUNDS FOR COMBATING BORNA DISEASE VIRUS AND FOR THE PREVENTION AND TREATMENT OF AFFECTIVE DISEASES AND OTHER DISORDERS ASSOCIATED WITH BDV INFECTIONS IN HUMANS AND ANIMALS
The invention concerns the use of 1-adamantane amines (amantadines) or structurally similar compounds for combating borna disease virus infections and for treating affective diseases and disorders...
|
|
|
6271264 |
Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants
The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective...
|
|
|
6114392 |
Agmatine, and polyaminoguanidine-bound heterocyclic compounds for neurotrauma and neurodegenerative diseases
The invention relates to the use of agmatine, in the treatment of acute neurotrauma (such as stroke) and degenerative disorders of the central and peripheral nervous system (such as dementia). The...
|
|
|
6066652 |
Method for treating diseases of the inner ear using adamantane derivatives
|
|
|
5962463 |
Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
Stimulating non-amyloidogenic processing by the activation of cell surface serotonin receptors linked to phospholipase and protein kinase C is described. Activation of the cell surface serotonin...
|
|
|
5939425 |
Method for treating a migraine
The migraine-treating effectiveness of a local anesthetic drug is significantly enhanced by coadministering dextromethorphan or dextrorphan.
|
|
|
5886051 |
Methods and compositions for the treatment of neurodegeneration
Methods and pharmaceutical compositions in unit dosage form for treating neurodegeneration in a human or non-human animal afflicted therewith wherein the active agent is a therapeutically effective...
|
|
|
5866585 |
Methods of treating tardive dyskinesia using NMDA receptor antagonists
A method for treating symptoms of patients diagnosed with tardive dyskinesia (TD) using NMDA receptor antagonists is disclosed. This invention illustrates that certain NMDA-receptor antagonists are...
|
|
|
5614509 |
Pharmaceutical agents for preventing the development of tolerance during the treatment with benzodiazepine-receptor-binding active ingredients
The use of NMDA receptor antagonists or their physiologically compatible salts for preventing the development of tolerance during the long-term treatment with benzodiazepine-receptor-binding active...
|
|
|
5614560 |
Method of preventing NMDA receptor-mediated neuronal damage
Disclosed is a method for reducing non-ischemic NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a compound of the formula shown in FIG. 1 (or a...
|
|
|
5597809 |
Treatment of optic neuritis
Methods of treating optic neuritis comprising administering a protective agent which inhibits glutamate-mediated retinal cell damage to a mammal at risk of developing optic neuritis.
|
|
|
5596020 |
Amino bi- and tri-carbocyclic alkane bis-aryl squalene synthase inhibitors
This invention relates to a class of novel amino bi- and tri-carbocyclic alkane compounds having bis-aryl substitution which exhibit squalene synthase inhibition properties. The bi- and...
|
|
|
5576355 |
Diamondoid derivatives for pharmaceutical use
A method of inhibiting viruses in which a virus is contacted with diamondoid alcohol, ketone, ketone derivative, adamantyl amino acid, quaternary salt or combinations thereof which have antiviral...
|
|
|
5506231 |
Treatment of aids dementia, myelopathy and blindness
Damage to CNS neurons of a human patient infected with a human immunodeficiency virus is reduced by administering an antagonist of the NMDA receptor complex.
|
|
|
5326786 |
5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo[alpha]heptalene derivative and pharmaceutical use
Compounds represented by the formula ##STR1## wherein R 1 and R 2 each represent a hydrogen atom or a protective group for a hydroxyl group, or R 1 and R 2 combine to represent a protective...
|
|
|
5158775 |
Aerosols of pyrido [1,2-a]pyrimidine compounds
A suspension type aerosol inhalations containing (a) 0.015 to 5.00% (w/w) of a pyrido[1,2-a]pyrimidine compound of the formula: ##STR1## where R is a n-propyl or allyl group, A is a tetrazolyl or...
|
|
|
5061703 |
Adamantane derivatives in the prevention and treatment of cerebral ischemia
A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R 1 and R 2 are identical or different, representing hydrogen or a...
|
|
|
4351847 |
Antiviral alpha, alpha-dialkyl adamantylethylamines
Warm-blooded animals are treated by administering to the animal a dosage, effective to prevent or to alleviate the symptoms of herpes virus, type II, of a compound of the formula I or its acid...
|
|
|
4346112 |
Composition and method for treating patients having Parkinson's Disease
Parkinson's Disease in animals is treated by administering to the animal 3-ethyl-aminodamantane in a pharmaceutically acceptable carrier.
|
|
|
4283422 |
3-Amino-4-homoisotwistane derivatives
Novel 3-amino-4-homoisotwistane derivatives of the formula, ##STR1## wherein R 1 is a hydrogen atom, a C 1 -C 4 alkyl group or a C 3 -C 5 alkenyl group, and R 2 is a C 1 -C 4 alkyl group or...
|
|
|
4248891 |
1-(1-Aminoalkyl)tricyclo[4,3,1,1.sup.2,5 ]undecanes
Compounds having the formula ##STR1## in which R is lower alkyl, and acid addition salts of said compounds. The compounds possess anti-RNA-viral activity and also an antiviral activity against...
|
|
|
4230725 |
Antiviral agent
Antiviral agents containing an effective amount of 1-amino-2,4-ethanobicyclo[3,3,1]nonane or salts thereof which are effective for the treatment or prevention of infectious diseases caused by...
|
|
|
4202892 |
Biocidal methyladamantyl hydrazines and pharmaceutical compositions containing them
The invention provides novel 1- or 2-adamantylmethyl hydrazines of the general formula A ##STR1## In this formula Ad is 1- or 2-adamantyl, R 1 and R 2 are the same or different and are each...
|
|
|
4148896 |
Antidepressant combination
Amantadine and molindone or their pharmaceutically suitable salts, useful for treatment of depression.
|
|
|
4124716 |
Process for the treatment of spasmodic conditions in humans
Process for the treatment of spasmodic conditions in humans by administering a compound of the general formula ##STR1## or a pharmacologically acceptable acid addition salt thereof to a human...
|
|
|
4122193 |
Drugs or medicines for influencing the central nervous system
Certain 1,3,5-trisubstituted adamantane compounds having central nervous system activity, especially anti-Parkinsonism activity, method of preparing same, and pharmaceutical compositions thereof,...
|
|
|
3975541 |
Insect repellent compositions having an N-substituted hydroxyalkyl amine as an active ingredient
Lower hydroxyalkyl amines in which at least one of the amino hydrogens is replaced by an acyclic monoterpenyl radical or hydrogenated acyclic terpenyl radical are useful repellents for insect...
|
|
|
3456057 |
PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING 3-AMINOTRICYCLO(4.3.1.1**3.8)UNDECANES
|
|
|
3433876 |
FUNGICIDAL COMPOSITION CONTAINING 3A,4,7,7A - TETRAHYDRO - 2,3,3A,4,5,6,7,7A- OCTAHALO - 4,7 - METHANOINDENE 1,8- DIONE DIIMINE AND METHOD OF USING THE SAME
|
|
|
3328251 |
Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
|
|
|
3310469 |
Pharmaceutical compositions and methods utilizing 1-aminoadamantane and its derivatives
|
|
|
3592934 |
Title is not available
|